%0 Journal Article
%T [Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects].
%A Yuan ZG
%A Ye SL
%J Zhonghua Gan Zang Bing Za Zhi
%V 32
%N 6
%D 2024 Jun 20
%M 38964901
暂无%R 10.3760/cma.j.cn501113-20240412-00200
%X Hepatocellular carcinoma (HCC) is a common type of poorly prognosticated malignant tumor. Surgical resection is the preferred treatment method for early-stage HCC. However, at the time of the initial diagnosis, fewer than 30% of patients with liver cancer are suitable for radical therapy. Systemic therapy plays an important role in the treatment process of patients with intermediate- to advanced-stage HCC, as it can effectively extend patients' survival time. With an emphasis on the status and role of systemic therapy for comprehensive management of HCC, this article summarizes the latest progress at home and abroad in the past five years, including first-line combined immunotherapy for advanced-stage HCC, second-line therapy selection, perioperative systemic therapy application, and combined therapy of systemic and local. Currently, the treatment model combined with local therapy has already become a new research hotspot in the treatment of advanced-stage HCC. Nevertheless, in the future, individualized and precise systemic therapeutic strategies will need further exploration.<BR>肝细胞癌（HCC）是一种常见且预后较差的恶性肿瘤，手术切除是治疗早期HCC的首选方法，然而不足30%的肝癌患者在初诊时适合根治性治疗。系统治疗在中晚期HCC患者的治疗过程中发挥重要的作用，可有效延长患者的生存时间。归纳近5年国内外关于中晚期HCC系统治疗的最新进展，包括晚期HCC的一线免疫联合治疗、二线治疗的选择、系统治疗围手术期应用以及系统治疗与局部治疗的联合疗法，并重点阐述了系统治疗在HCC的全程管理中的地位和作用，以期为HCC系统治疗提供思路。对于，联合局部治疗的治疗模式已成为治疗晚期HCC新的研究热点，未来将进一步探索个体化、精准化的系统治疗策略。.